Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Metastatic prostate cancer].

Jean-Pierre Droz1, Aude Flechon, Catherine Terret

  • 1Département de Cancérologie médicale, Centre Léon Bérard, 69373 Lyon 08. droz@lyon.fnclcc.fr

La Revue Du Praticien
|March 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perinatal insights into human T-lymphotropic virus 1 in western French Guiana: Unmasking a silent disease.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

European urology oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Metastatic prostate cancer is incurable, with treatments focusing on palliative care and improving quality of life. Hormone resistance develops within two years, necessitating alternative therapeutic strategies.

Area of Science:

  • Oncology
  • Urology

Background:

  • Metastatic prostate cancer is an incurable, hormonodependent malignancy.
  • Current treatments offer palliative care, with a median survival of 3 years.
  • Hormone resistance develops in a median of 2 years, limiting treatment efficacy.

Purpose of the Study:

  • To review current treatment strategies for metastatic prostate cancer.
  • To highlight the challenges of hormone resistance and symptom management.
  • To emphasize the importance of quality of life in palliative care.

Main Methods:

  • Review of existing literature on prostate cancer treatment.
  • Analysis of therapeutic options including androgen blockade, radiotherapy, and chemotherapy.
  • Evaluation of treatment side effects and symptom control.

Related Experiment Videos

Main Results:

  • Androgen deprivation is the primary treatment, but resistance is common.
  • Key symptoms include pain, urinary obstruction, and neurological complications.
  • Side effects of androgen deprivation include impotency and osteoporosis.

Conclusions:

  • Metastatic prostate cancer management is primarily palliative.
  • Addressing hormone resistance and improving patient quality of life are critical.
  • Multimodal treatment approaches are essential for symptom control.